Scripbox raised around $9 million in 2023 and 2024 through two funding rounds, primarily from existing investor Accel. It sought to raise funds from new investors last year but eventually secured $5 ...

Epsilogen and TigaTx have not disclosed the financial terms of the deal. Credit: RealPeopleGroup via Getty Images. UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that ...

Combined clinical-stage company benefits from a strong pipeline: MOv18 IgE, an anti-Folate Receptorα IgE antibody, currently in a Phase Ib Proof of Concept trial in platinum-resistant ovarian cancer.

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

Last checked, it was down 3.45 per cent at Rs 17.33. At this price, the scrip has corrected 21.08 per cent in six months. The bank reported an 8.2 per cent year-on-year (YoY) growth in its loans ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

If both genetic parents are Rh-negative, their children will be, too. The pregnant parent should have their blood type, including Rh factor, tested and antibody screening done if indicated as part of ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...

However, in a recent update, the Hon’ble Securities Appellate Tribunal (SAT) passed an order on March 5, 2025, staying the SEBI’s order from January 31, 2025. The stay was granted after Keyur ...